Cambridge, UK - 28th August 2018
Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces that it has agreed to amend the terms of the Convertible Loan Agreement (“Loan”) dated 18th April 2017, extending the loan until 18th April 2019.
The conversion price of any outstanding loans and any accrued interest into shares and warrants has been set at 2.75p per share and such warrants are exercisable at any time for 60 months from the date on which the warrants were granted. The 2.75p conversion price represents a 8% premium to the closing price on 23 August 2018, the day prior to the amended agreement being signed.
Market Abuse Regulation (MAR) Disclosure. Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the publication of this announcement via a Regulatory Information Service and accordingly, this inside information is now considered to be in the public domain.Download News